Drugs / AGN-151586
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07756580 | Aug 2026 → Mar 2027 expected | — | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT06834789 | Feb → Nov 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06151561 | Jan → Apr 2024 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05496335 | Aug 2022 → May 2023 | — | AbbVie | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07730554 | Jul → Oct 2026 expected | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04096326 | Sep 2019 → Sep 2020 | — | Allergan | Completed | Met primary |
| Phase 34 trials · 2 met primary | ||||||
| Phase 3 | NCT06308198 | Mar 2024 → Feb 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT05248867 | Mar 2022 → Mar 2023 | — | AbbVie | Completed | Met primary |
| Phase 3 | NCT05248880 | Mar 2022 → Feb 2023 | — | AbbVie | Completed | Met primary |
| Phase 3 | NCT05248893 | Feb 2022 → Jun 2023 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN-151586 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07730554 ↗ |
| Route | Intramuscular | “AGN-151586 lowest dose, IM injections in the glabellar complex on Day 1.” NCT04096326 ↗ |